Evolus (EOLS) Investor presentation summary

Market opportunity and growth drivers

• Aesthetics market remains underpenetrated, supporting long-term growth with millennials and Gen Z driving demand and repeat usage, shifting the category toward a lifestyle orientation.

• Neurotoxin and dermal filler markets are projected to grow at 7% and 4% CAGRs, respectively, through 2028, with total market size reaching $4.3B for fillers and $3.7B for neurotoxins.

• Company has consistently outpaced the market with double-digit revenue growth for six consecutive years.

Portfolio and product innovation

• Expanded from a single-product to a multi-product portfolio, including Jeuveau® (neurotoxin) and Evolysse® (HA gels), with strong synergy as 85% of practices offer both product types.

• Jeuveau® holds a mid-teens share of the U.S. neurotoxin market and is expanding internationally.

• Evolysse® is the first HA gel with Cold-X® technology, offering non-inferiority and statistical superiority to competitors, and is the only HA recognizing weight loss as a factor in wrinkle formation.

• Portfolio execution includes recent U.S. launches and upcoming European launches, with regulatory milestones expected through 2027.

Business model and digital ecosystem

• Operates a cash-pay business model, eliminating third-party reimbursement and enabling flexible, customer-driven pricing.

• Integrated digital platform drives loyalty, engagement, and growth through data-driven insights, co-branded marketing, and seamless rewards programs.

• Evolux® and Evolus Rewards™ loyalty programs incentivize multi-product adoption and repeat usage, with over 1.4 million enrollments and growing share of redemptions from existing patients.